Putney launches generic med for dogs
PHOTo / Tim Greenway
Jean Hoffman, president and CEO of Putney
Putney Inc., a pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has received FDA approval for a generic drug to treat skin infections in dogs.
The company's Cefpodoxime Proxetil is the only generic with FDA-approved equivalence to the brand-name Simplicef, according to a company press release.
Jean Hoffman, president and CEO of Putney, expects the company's new product to penetrate and expand the $25 million market for Cefpodoxime Proxetil.
"Pet owners are looking for more affordable, equivalent medications to treat their pet family members, just like the FDA-approved generic drugs that they are comfortable using when doctors prescribe medication for their human family," says Hoffman in the release.
Based on the company's analysis of drugs approved by the FDA's Center for Veterinary Medicine, it found that only 7% of approved drugs for dogs and cats have a veterinary generic equivalent. Putney's Cefpodoxime Proxetil tablets will cost at least 25% less to veterinarians than the brand-name product, according to COO TJ Dupree.
With the addition of this product, Putney now has three FDA-approved veterinary generic medicines on the market and Hoffman says the Putney team is working on more than 20 new products in various phases of development and FDA review.
"We believe we have the deepest pipeline in veterinary medicine, aimed at providing veterinarians and pet owners with FDA-approved generics of pet medicines where price is a barrier to prescribing and using the right drug for each pet's medical need. The approval of Putney's bio-equivalent Cefpodoxime Proxetil is just the beginning," says Hoffman.
Read more
Putney sold for $200M to UK veterinary company; founder to leave
Most Recent
Most Recent
Comments